Two large trials reached different conclusions about SGLT2 inhibitors; the EMPACT-MI (empagliflozin within 14 days) was neutral on the primary composite of first HF hospitalization or all-cause death, though several HF outcomes favoured treatment. Here, SLC5A2 is linked to hydrops fetalis.